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ABSTRACT 
 
Antibiotic Resistance: Multi-drug Profiles 
and Genetic Determinants  
by 
LaShan D. Taylor 
 
Antimicrobial susceptibility profiles were assembled for isolates of Moraxella catarrhalis 
collected from the Mountain Home Veteran's Affairs Medical Center (VAMC) clinical 
laboratory in Johnson City, Tennessee. The goal of the study was to identify isolates for genetic 
characterization using comparisons of susceptibility profiles. Isolates of Moraxella catarrhalis 
collected from July 1984 through 1994 were analyzed for β-lactamase production using a 
Cefinase disk assay.  
 
A multi-drug profile consisting of 11 β-lactam antibiotics was performed on the 41 M. 
catarrhalis isolates. Kirby Bauer disk assays were performed for 7 cephalosporin and 4 non-
cephalosporin antibiotics.  
 
In summary, 2 observations implicate more complex resistance determinants than the 2 known 
forms of the BRO β-lactamase. First, there was overlap in the ranges of inhibition zones. Second, 
several isolates had antibiotic-specific deviations from typical profiles. These data suggest either 
more variation in the M. catarrhalis BRO β-lactamase than described or contributions to 
resistance from undescribed determinants.  
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CHAPTER 1 
INTRODUCTION 
Moraxella catarrhalis Profile 
 Moraxella (Branhamella) catarrhalis, a Gram-negative diplococcus previously thought 
to be a commensal of the upper respiratory tract, has more recently gained recognition as an 
emerging pathogen (Enright and McKenzie 1997). Moraxella (Branhamella) catarrhalis is the 
3rd  most common bacterium isolated from the middle-ear fluid of children with otitis media and 
it is frequently found in the sputum of adults with acute exacerbations of chronic obstructive 
pulmonary disease (Bootsma et al. 2000). A striking feature of M. catarrhalis is the rapid 
worldwide and local increase in β-lactamase producing strains (Bootsma et al. 2000; Walker et 
al. 2000) (Fig.1). This dramatic rise probably represents the fastest increase in prevalence of any 
known β-lactamase within a bacterial species (Wallace et al. 1989). 
Resistance to β-lactam antibiotics has emerged in a number of pathogens over the past 
years, including M. catarrhalis  (Jacoby 1994). The 1st reports of β-lactamase production in M. 
catarrhalis appeared in 1977 (Malmvall et al.1977; Percival et al. 1977), and a rapid increase in 
the frequency of β-lactamase producing strains was reported from different localities shortly 
thereafter (Doern et al. 1980; Doern and Jones 1988; Wallace et al. 1989). Currently, greater than 
90% of M. catarrhalis strains are clinically resistant to β-lactam antibiotics such as penicillin, 
ampicillin, and amoxicillin (Doern et al. 1996; Walker et al. 2000). Several classification 
schemes of β-lactamases have been proposed based on the enzyme hydrolytic spectrum, 
susceptibility to inhibitors, genetic localization (plasmid or chromosome), DNA gene or amino 
acid protein sequence (Thornsberry 1991). 
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β-lactam antibiotics belong to a family of antibiotics characterized by a β-lactam ring, the 
presence of which aids the antibiotic in exerting its bactericidal activity. Penicillins, 
cephalosporins, clavams (or oxapenams), cephamycins, and carbapenems are members of the β-
lactam family of antibiotics. The antibiotic activity results in the inactivation of a set of 
transpeptidases that catalyze the final cross-linking reactions of peptidoglycan synthesis (Yao 
and Moellering 1991).  
 The production of β-lactamases is the most common mechanism of β-lactam resistance 
and, as these enzymes are frequently plasmid encoded (Jacoby 1994), resistance can be easily 
transferred between bacteria. Probably the most clinically important characteristic of a β-
lactamase is its ability to hydrolyze β-lactam antibiotics (Bush and Sykes 1986). However, an 
alternate mechanism of antibiotic resistance has emerged in several species (Spratt 1994). This 
type of resistance is mediated by target alterations, or the development of altered penicillin-
binding proteins (PBPs) (Dowson et al. 1994; Maiden 1998). Uptake and recombination of DNA 
by naturally competent bacteria may result in mosaic genes, the products of which have 
decreased affinity for β-lactam antibiotics (Dowson et al. 1994; Maiden 1998). Although, the β-
lactamase encoding bla locus of M. catarrhalis does not appear to be a mosaic gene, its 
dissemination mediated by transformation and recombination is reminiscent of this process 
(Bootsma et al. 2000). 
BRO-1 and BRO-2 Alleles 
Moraxella catarrhalis strains may produce either BRO-1 or BRO-2 β-lactamase, which 
can be distinguished on the basis of differences in their isoelectric focusing pattern (Wallace et 
al. 1989). BRO-1 strains represent the majority of β-lactamase producing M. catarrhalis and 
express higher levels of resistance to ampicillin (Bootsma et al. 2000).  BRO-1 and BRO-2 were 
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shown to be alleles of the same chromosomal locus and they were also almost identical in DNA 
sequence, differing in only 5 base pairs, of which 1 resulted in an amino acid substitution 
(Bootsma et al. 1996). The β-lactamase gene of M. catarrhalis has been shown to be expressed 
as a 33-kDa lipoprotein associated with the outer membrane (Bootsma et al. 1999). A 33-kDa 
lipoprotein thus far has been described only for β-lactamases of Gram-positive species, 
suggesting that the BRO β-lactamase was derived from a Gram-positive bacterium. A significant 
difference was observed in the promoter region of the 2 BRO alleles, possibly explaining the 
lower expression level of BRO-2 compared with BRO-1. Also, the distinct G+C content of the 
bla locus compared to those of other M. catarrhalis genes is strong evidence for a relatively 
recent acquisition. The present data suggest that BRO β-lactamase originated from a Gram-
positive bacterium and that its lipidation is a remnant of its origin (Bootsma et al. 1999).  
β-lactam Antibiotics 
Penicillins comprise a group of natural and semisynthetic antibiotics consisting of a β-
lactam ring fused to a thiazolidine ring (Yao and Moellering 1991). The antibiotic actions of 
penicillins are based on their ability to inhibit a number of bacterial enzymes, known as 
penicillin binding proteins (PBP), that are essential for peptidoglycan synthesis (Yao and 
Moellering 1991). Cephalosporins comprise a group of antibiotics that are derivatives of the 
fermentation products from the fungus Cephalosporium (Yao and Moellering 1991). The 
structure is composed of a β-lactam ring fused to a dihydrothiazine ring (Yao and Moellering 
1991). Cephalosporins bind to PBPs, thereby inhibiting synthesis of peptidoglycan for the 
bacterial cell wall. Cephalosporins are often classified based on general features of their 
antibacterial activity. First generation cephalosporins have strong Gram-positive activity and 
modest Gram-negative activity (Yao and Moellering 1991). Second-generation cephalosporins 
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act against certain β-lactamases found in Gram-negative organisms (Yao and Moellering 1991). 
Third generation cephalosporins are generally less effective against Gram-positive cocci, but 
more effective against the Enterobacteriaceae (Yao and Moellering 1991). Aztreonam is a 
monobactam antibiotic that binds to PBP-3 of Gram-negative aerobes. It is often given 
intravenously and its activity is limited to Gram-negative bacilli (Yao and Moellering 1991). 
Imipenem is a semisynthetic derivative of thienamycin, which is produced by Streptomyces spp. 
(Yao and Moellering 1991). Imipenem binds to PBP-1 and PBP-2 of Gram-negative and Gram-
positive bacteria leading to cell elongation and lysis (Yao and Moellering 1991).  
Antibiotic Resistance 
Antibiotic resistance among many pathogenic microbes has been increasing during the 
last decade. It is mostly associated with: a) overuse of antibiotics in outpatient settings; b) 
unwarranted use of very broad spectrum antibiotics; c) poor standards for bacterial identification 
and patient monitoring; d) ineffective hospital infection control over nosocomial transmission of 
resistant strains.  
Resistance to antibiotics can be intrinsic or acquired. Intrinsic resistance dictates the 
spectrum of activity of the antibacterial and it is always present (Thornsberry 1991).  For 
example, Gram-negative bacteria are intrinsically resistant to cloxacillin and vancomycin due to 
the Gram-negative cell wall being multi-layered with a lipoprotein-lipopolysaccharide-
phospholipid outer membrane external to the relatively thin peptidoglycan layer that protects the 
cell wall from many antibiotics and enzymes (lysozyme) (Thornsberry 1991). Of increased 
clinical significance is acquired resistance, in which bacteria that were previously sensitive to 
antibiotics become resistant. Bacteria can acquire resistance through chromosomal mutations or 
acquisition of genetic material (e.g., plasmids, transposons), which confers resistance to 
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antibiotics (Thornsberry 1991). Transfer of these plasmids from 1 organism to another can lead 
to widespread resistance. Of great concern is the potential for 1 species of bacteria (e.g., 
Enterococcus) to transfer plasmids to a different species of bacteria (e.g., Staphylococcus) 
(Thornsberry 1991). Changes in resistance patterns can occur after years of exposure to an 
antibiotic (e.g., penicillin-resistant pneumococcus) or can develop during the course of therapy 
for an infection (e.g., extended-spectrum β-lactamases that are seen in certain Gram-negative 
bacilli).  
The mechanism by which bacteria become resistant to antibiotics often reflects the 
mechanisms by which antibiotics kill bacteria. After an antibiotic penetrates the cell wall or 
membrane of the bacteria, it targets a specific bacterial enzyme (e.g., penicillin-binding protein, 
DNA gyrase) or ribosome, thereby interfering with bacterial protein synthesis or replication. The 
mechanisms of resistance to different antibiotics, therefore, include the following: decreased 
penetration through the bacterial cell membrane, enzymatic degradation or inactivation of the 
antibiotic, alteration of the target site and active efflux of the antibiotic out of the bacteria. 
Resistance to a given class of antibiotics can occur by several mechanisms. Furthermore, as 
drugs of a similar class have the same mechanism of action, cross-resistance between drugs 
within the same class is often expected.  
The most common mechanism of antimicrobial resistance is the production of enzymes 
that inactivate or modify the antibiotic (Medeiros 1997). Examples include the production of β-
lactamases by many Gram-positive and Gram-negative organisms as well as aminoglycoside-
modifying enzymes in Gram-negative pathogens (Livermore et al. 2001). Within the Gram-
negative bacteria, many different β-lactamases have been identified. While some classes of β-
lactamases may cause degradation of an entire class of β-lactam antibiotic (e.g., penicillinase, 
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cephalosporinase, carbapenemase), others are more specific to a smaller group of antibiotics 
(e.g., development of resistance to 3rd generation cephalosporins in certain Klebsiella species) 
(Livermore et al. 2001). Apart from protecting the producing bacteria against β-lactam 
antibiotics, the β-lactamase of M. catarrhalis can also have indirect pathogenic effects by 
blocking antibiotic therapy of concomitant infections with more dangerous respiratory pathogens 
such as pneumococci, as suggested by Wardle (1986) and as experimentally confirmed by Hol et 
al. (1994).   
An alteration in the target site is another common mechanism through which bacteria 
become resistant to antibiotics. β-lactam antibiotics bind to PBPs, enzymes involved in cell wall 
synthesis of bacteria. By binding to PBPs, the antibiotic interferes with cell wall synthesis, 
resulting in inhibition of bacterial cell division. Changes in PBPs have resulted in the 
development of penicillin-resistant Streptococcus pneumoniae and methicillin-resistant 
Staphylococcus aureus. Similarly, an alteration in DNA gyrase, the target site of quinol1 activity, 
is responsible for resistance in Gram-negative bacteria.   
Antibiotic Resistance Testing 
Of the various tests for the detection of β-lactamases, a direct test is feasible in species 
where few enzyme types occur and where enzyme production has clear implications for therapy 
(Livermore and Brown 2001). For example, the nitrocefin test is a chromogenic cephalosporin 
that changes from yellow to red upon hydrolysis (Livermore and Brown 2001). It is the most 
sensitive test for most β-lactamases.  
       The clinical goal of antimicrobial susceptibility testing is to predict the in vivo success or 
failure of antibiotic therapy. Tests are designed to measure the growth response of an isolated 
organism to a particular drug or drugs under standardized conditions. The results of antimicrobial 
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susceptibility testing should be combined with clinical information and experience when 
selecting the most appropriate antibiotic (Thornsberry 1991). The disk-diffusion method (Kirby-
Bauer disk assay) is more suitable for routine testing in a clinical laboratory where a large 
number of isolates are tested for susceptibility to numerous antibiotics (Thornsberry 1991). An 
agar plate is uniformly inoculated with the test organism and a paper disk impregnated with a 
fixed concentration of an antibiotic is placed on the agar surface (Thornsberry 1991). Growth of 
the organism and diffusion of the antibiotic commence simultaneously resulting in a circular 
zone of inhibition in which the amount of antibiotic exceeds inhibitory concentrations 
(Thornsberry 1991). The diameter of the inhibition zone is a function of the amount of drug in 
the disk and susceptibility of the microorganism (Thornsberry 1991). This test must be 
rigorously standardized because zone size is also dependent on inoculum size, medium 
composition, temperature of incubation, excess moisture and thickness of the agar (Thornsberry 
1991). If these conditions are uniform, reproducible tests can be obtained and zone diameter is a 
function of the susceptibility of the test organism. Zone diameter can be correlated with 
susceptibility as measured by the dilution method. Further correlations using zone diameters 
allow for the designation of an organism as clinically "susceptible", "intermediate", or "resistant" 
to concentrations of an antibiotic which can be attained in the blood or other body fluids of 
patients requiring chemotherapy (Livermore et al. 2001). 
 The susceptibility category implies that an infection may be appropriately treated with 
the usual dosage of the antimicrobial agent recommended for the type of infection present 
clinically. The resistant category predicts possible failure of the antimicrobial agent (Thornsberry 
1991). Resistant strains are not inhibited by the usually achievable systemic concentrations of the 
agent with normal dosage schedules and/or fall in the range where specific microbial resistance 
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mechanisms are likely and/or where clinical efficacy has not been reliable in treatment studies 
(Thornsberry 1991). The intermediate category provides a buffer zone between the susceptible 
and resistant categories. It is intended to avoid major discrepancies in interpretation due to small, 
uncontrolled technical factors in testing (Thornsberry 1991). It should also be noted that 
susceptibility and resistance is a continuous scale, and that some organisms fall in a "gray zone" 
which is difficult to categorize at 1 end of the spectrum. Organisms in this category may or may 
not respond to therapy with the tested agent, depending on many factors, which include the site 
of the infection and the ability to increase the dose of the agent (Thornsberry 1991).   
This study was conducted in order to assess the susceptibility of Moraxella catarrhalis 
isolates from the Johnson City VAMC. The susceptibility information was used to create a 
profile of the isolates for further study. Profiles were analyzed statistically to uncover isolates 
that fall out of the normal range of susceptibility. Those isolates were classified as deviant and 
require further analysis, emphasizing the purpose of the study and the question. The question I 
sought to answer was, what is the magnitude of phenotypic variation in antibiotic profiles within 
a bacteria population? 
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Figure 1. Proportion of β-lactamase Producers Among the VAMC Population 
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CHAPTER 2  
MATERIALS AND METHODS 
Bacterial Strains and Cultures 
 The vast majority of M. catarrhalis strains in the James H. Quillen Veterans Affairs 
Medical Center (VAMC) collection were isolated from sputum samples of patients (Walker et al. 
2000). The collection includes over 1000 isolates that were obtained during a 10-year time 
period (1984-1994). An additional 40 isolates from previous years (1983-1984) and 40 isolates 
from subsequent years (1994-1998) were available for testing. Isolates from the 10-year period 
have been intensely studied (Walker et al. 1998; Walker et al. 2000; Walker and Levy 2001), 
while the pre and post-dated isolates were not subjected to Kirby Bauer disk assay antibiotic 
testing.  
Strains in the collection were frozen in skim milk to prevent desiccation and stored at       
-70°C.  Aliquots of cells from frozen culture were used to inoculate Todd Hewitt (TH) agar 
plates and incubated overnight at 35°C.  
Cefinase Disk Assay for β-lactamase Activity 
 Nitrocefin disks, (“Cefinase”; Becton Dickson, Sparks, MD) were used to assay β-
lactamase activity.  Cefinase disks were labeled with strain number corresponding to VAMC 
collection number, placed on sterile aluminum foil, and moistened with 1 drop of sterile dH2O. 
An inoculating loopful of cells was then spread directly from a plate onto a Cefinase disk and the 
reaction was allowed to proceed for a maximum of 15 minutes. A positive reaction, observed as 
a color change from yellow to red, was interpreted as indicating β-lactamase production (Fig. 2). 
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Kirby Bauer Disk Assay for β-lactamase Sensitivity Tests 
 Each of 40 strains from the 10-year VAMC collection of M. catarrhalis was tested for 
susceptibility to 11 different β−lactam antibiotics, 7 of which were cephalosporins and 4 were 
non-cephalosporins. The following cephalosporins were tested: ceftazidime (Becton Dickinson, 
Cockeysville, MD), cefaclor (Becton Dickinson, Cockeysville, MD), cefixime (Becton 
Dickinson, Sparks, MD), ceftriaxone (Difco, Detroit, MI), cefotaxime (Difco, Detroit, MI), 
cefuroxime (Becton Dickinson, Cockeysville, MD), and cefamandole (Becton Dickinson, 
Cockeysville, MD). Non-cephalosporins included: penicillin G (Becton Dickinson, Sparks, MD), 
amoxicillin/clavulanic acid (Becton Dickinson, Sparks, MD), aztreonam (Becton Dickinson, 
Sparks, MD), and imipenim (Difco, Detroit, MI).  
The Kirby Bauer disk assay was used in all antibiotic testing according to NCCLS 
guidelines (NCCLS, 1997). Using a sterile inoculating loop, M. catarrhalis colonies were 
transferred from plates into sterile 10 ml tubes and mixed by vortexing for 15-20 seconds. To 
standardize the number of cells in each antibiotic assay, turbidity of the suspension was visually 
adjusted with sterile 0.85% NaCl to approximately that of a 0.5 McFarland turbidity standard 
(1.5 x 108 CFU/ml).  
Within 15 minutes of adjusting the inoculum to a McFarland 0.5 turbidity standard, 
sterile cotton swabs were dipped into the suspension and rotated against the wall of the tube 
above the liquid to remove excess suspension. Cotton swabs were used to inoculate agar plates 
by swabbing each plate 3 times, rotating the plate approximately 60° between swabs to ensure 
even distribution. The sides of the petri plate were avoided and care was taken to prevent 
aerosols. The inoculum was allowed to be absorbed for at least 3 minutes but no longer than 15 
minutes before applying Kirby Bauer disks (Fig. 3). 
17 
 
 Kirby Bauer disks were applied to the agar surface by using a dispenser and applying 
gentle pressure with sterile forceps to ensure complete contact of disk with agar. Disks 
impregnated with different antibiotics were separated by a minimum of 24 mm from center to 
center and no more than 5 disks were placed on a 100 mm plate.  
Plates were incubated for 16-18 hours at 35°C in an ambient-air incubator. Susceptibility 
was measured only if a lawn of bacteria was present. To score susceptibility, plates were rested 
lid down on a black non-reflecting surface and the diameter of the inhibition zone was measured 
to the nearest whole millimeter by holding a caliper micrometer against the back of the plates. 
Plates were examined visually for isolated colonies within the inhibition zone that may have 
represented resistance. Because plates contained bacterial cells from a single strain of M. 
catarrhalis, multi-drug profiles were easily assembled.  
Statistical Analysis 
 The multi-drug profile was used as a method for inferring genetic variation and 
highlighting isolates for further sequence analysis and determining possible variation among and 
within antibiotics. A strain was considered significantly different from others in its susceptibility 
if its inhibition zone was greater than 2 standard deviations from the mean. To assess 
concordance of multi-drug profiles, strains showing significant deviation from means were 
evaluated in a non-quantitative manner. For example, if 2 strains showed significant deviation 
from means in regard to the same antibiotic, then the remainder of the profile was examined to 
determine if the 2 strains showed similar susceptibilities to the remaining antibiotics. To compare 
β-lactamase producers with β-lactamase non-producers, 2-sample t-tests, and confidence 
intervals were computed using Minitab (Minitab, Inc. 1993). Grubbs outlier test was also 
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performed in order to assess if there existed any isolates detected as deviants other than those 
identified by 2 standard deviations (Graphpad, Inc.). 
Haplotype Analysis 
 Haplotype profiles were previously studied for the VAMC isolates tested. Of those some 
of the isolates selected for analysis had identical multi-locus genotypes. Each of 8 genotypes was 
represented by 2 or 3 isolates. Isolates representing 1 genotype were all β-lactamase non-
producers, isolates representing 6 genotypes were all β-lactamase producers (Table 1). Genotype 
109CC was represented by 2 β-lactamase non-producers (isolates #604; #907) and 1 β-lactamase 
producer (isolate #830) (Table 1).  
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Figure 2. Nitrocefin Disk Assay for β-lactamase Activity. A red color change indicates that 
cleavage has occurred and that a β-lactamase producer is present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Kirby Bauer Disk Assay. Antibiotic susceptibility plates showing antibiotic disks 
placed on an agar plate incubated with a lawn of bacteria. The “halo” around the disk indicates 
the susceptibility of the bacteria to that particular antibiotic. A small zone indicates resistance 
and a large zone indicates susceptibility. 
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CHAPTER 3 
RESULTS 
Multi-Antibiotic Profiles 
 A total of 14 separate antibiotic profiles were found among the 41 isolates tested. Many 
of the isolate profiles were typical which means that inhibition zones produced in response to 
any of the antibiotics did not deviate from the mean by more than 2 standard deviations. Among 
the β-lactamase producers, there were 8 different profiles consisting of 1 typical and 7 deviant 
profiles (Table 1). The deviant profiles included antibiotic-specific reductions in susceptibility, 
including: a cefuroxime specialist (#250); isolates with low susceptibility to amoxicillin/ 
clavulanic acid (#830 & 785); a cefixime specialist (#417); an isolate especially susceptible to 
ceftazidime (#691); and an aztreonam and cefamandole specialist that was also sensitive to 
cefotaxime (#566). The profile also included multi-specialists such as isolate #359 which was 
highly sensitive to aztreonam, ceftazidime, ceftriaxone, and cefotaxime, and isolate #813 which 
was highly sensitive to cefaclor, cefixime, ceftriaxone, cefotaxime, cefuroxime, cefamandole, 
and penicillin G.  
 Among the β-lactamase non-producers there were 5 unique profiles and 1 typical profile 
(Table 1). Isolate #604 had high resistance to cefuroxime, while isolate #123 showed 
significantly lower susceptibility to ceftazidime, and isolate #444 was more sensitive to 
aztreonam. Isolate # 347 appears to have been a multi-specialist with increased sensitivity to 
both cefaclor and cefamandole. Isolate #474 appeared unique in showing resistance to 
amoxicillin/clavulanic acid, with sensitivity to ceftriaxone and imipenem. 
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Comparisons of β-lactamase Producers and Non-Producers 
β-lactamase producers were significantly less susceptible than non-producers to 9 of the 
11 antibiotics (Table 2). Only ceftazidime and cefotaxime had similar sized inhibition zones in 
producers and non-producers (Table 2). Among the non-cephalosporin antibiotics, only the 
response to aztreonam was not significantly different between the β-lactamase producers and β-
lactamase non-producers (Table 2). 
Outlier Test 
 Grubbs’ outlier test identified isolates that were outliers relative to the means. Isolates 
with large z values are considered outliers. Among the non-producers, isolates #474, #123, and 
#347 were identified as outliers (Table 3). Among the producers, isolates #691, #056, #359, and 
#813 were identified as deviant isolates by the Grubbs’ test (Table 3). Isolates with large deviant 
patterns include isolate #813, which was an outlier for 4 out of 11 antibiotics and was identified 
as farthest from the mean, but not quite significantly different in susceptibility to 1 other 
antibiotic (Table 3). 
Haplotype Comparisons 
 Many isolates were grouped in pairs based on identical multi-locus genotypes (Walker 
and Levy, 2001). Letter “A” denotes genotype #444DC, which contains 2 unique isolates, #444 
and #546. Isolate #546 had a typical profile while isolate #444 showed increased susceptibility to 
the antibiotic aztreonam. Letter “B” denotes genotype 109CC, which consisted of 3 separate 
isolates, #604, #830, and #907. Isolates #907 and #604 were both β-lactamase non-producers and 
isolate #830 was a β-lactamase producer. Isolate #907 displayed a typical profile, while isolate 
#604 showed decreased susceptibility to cefuroxime. Letter “C” identified isolates #813 and 
#417 that were both β-lactamase producers and showed deviant susceptibility profiles. Isolate 
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#813 displayed a deviant profile with increased susceptibility to 7 of 11 antibiotics (cefaclor, 
cefamandole, cefixime, cefotaxime, ceftriaxone, cefuroxime, and penicillin G).  Isolate #417 
displayed increased susceptibility to only 1 antibiotic (cefixime). Letter “D” denoted haplotype 
396AB, which contained isolates #566 and #785. Isolate #566 displayed decreased susceptibility 
to both cefamandole and aztreonam and displayed increased susceptibility to cefotaxime. In 
contrast, isolate #785 displayed increased resistance to amoxicillin. Letter “E”, haplotype 
418CC, contained isolates #944, #770, and #980, which all displayed a typical antibiotic profile. 
Letter “F”, haplotype 709CC, represented by isolates #712 and #709 also displayed a typical 
antibiotic profile.  
   
 
.  
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Table 1. Moraxella catarrhalis Strains Tested for Susceptibility to 11 Antibiotics. Diameters of 
the inhibition zone in response to Kirby Bauer disk assays are shown in millimeters. Strain 
genotypes are also shown (Walker and Levy 2001). Strains are grouped by presence or absence 
of β-lactamase activity. Isolates are sorted beginning with those that are typical (no significant 
deviations for any antibiotics), followed by 6 groups of isolates with identical profiles. Note: A, 
B, C, D, E, and F denote 6 genotypes represented by 2-3 isolates each. Highlighted and italicized 
items fall beyond 2 standard deviations of either susceptibility or resistance. Red items represent 
isolates that test as both outliers (Grubbs’, 2000) and fall greater than 2 standard deviations (sd) 
from the mean. Blue items represent isolates 2 standard deviations from the mean, but not 
detected by Grubbs’ outlier test. Abbreviations: strain = Moraxella catarrhalis VAMC number; 
β-lac = β-lactamase positive or negative; Cefac = cefaclor; Cefam = cefamandole; Cefix = 
cefixime; Cefotax = cefotaxime; Ceftaz = ceftazidime; Ceftria = ceftriaxone; Cefuro = 
cefuroxime; Amox = amoxicillin /clavulanic; Aztre = aztreonam; Imipe = Imipenem; Penic = 
penicillin G; Geno = genotype; Id = Isolates with the same letter represent isolates with identical 
genotypes. 
 
Strain β-lac Cefac Cefam Cefix Cefotax Ceftaz Ceftria Cefuro Amox Aztre Imipe Penic Geno Id 
#907 Neg 37.0 29.0 26.0 32.3 40.0 30.0 36.0 35.0 24.8 35.4 28.0 109CC B 
#150 Neg 33.0 35.6 34.0 29.0 42.6 44.0 29.5 46.0 30.0 46.0 37.7 144GE  
#337 Neg 39.0 41.0 31.0 44.0 38.0 45.0 41.0 47.0 7.5 49.4 44.5 151DC  
#190 Neg 41.4 40.0 36.0 46.0 46.5 49.2 36.0 44.0 32.0 50.4 44.0 190GE  
#546 Neg 30.0 30.0 22.0 36.0 42.7 38.4 28.0 46.0 31.4 42.0 39.0 444DC A 
#587 Neg 34.0 36.0 38.0 41.0 35.0 37.6 38.0 43.0 33.0 44.5 34.0 587AB  
#474 Neg 40.0 38.0 42.0 31.0 46.0 63.0 42.0 24.0 18.0 70.0 40.0 474KG  
#444 Neg 40.0 44.0 44.0 50.0 48.0 52.7 34.0 54.0 56.0 52.0 48.0 444DC A 
#347 Neg 54.0 60.0 26.0 30.0 42.0 30.0 49.0 38.0 35.0 47.5 31.0 347AB  
#123 Neg 33.0 38.0 22.0 27.6 24.0 25.6 30.0 40.5 35.0 39.5 40.0 123GE  
#604 Neg 38.0 27.0 30.0 38.4 42.0 42.0 14.0 40.0 22.0 42.0 34.0 109CC B 
 Mean 38.1 38.1 31.9 36.8 40.6 41.6 34.3 41.6 29.5 47.2 38.2   
 Sd 6.1 8.6 7.2 7.2 6.4 10.5 8.7 7.4 11.6 8.6 5.8   
 +2 Sd 50.3 55.2 46.4 51.3 53.3 62.5 51.7 56.4 52.7 64.4 49.8   
 -2 Sd 26.0 20.9 17.4 22.4 27.9 20.6 16.9 26.8 6.3 29.9 26.6   
               
               
Strain β-lac  Cefac Cefam Cefix Cefotax Ceftaz Ceftria Cefuro Amox Aztre Imip Penic Geno Id 
#844 Pos 12.0 15.0 24.0 30.0 40.0 24.2 23.3 34.6 23.5 32.0 0.0 067AB  
#685 Pos 15.0 12.0 22.0 21.5 35.0 22.0 17.6 31.6 12.0 31.5 0.0 077AB  
#430 Pos 24.0 10.0 27.0 33.8 40.0 24.0 27.0 40.0 30.5 39.4 5.3 098CC  
#113 Pos 18.0 15.0 20.0 34.5 39.3 33.4 14.0 38.0 22.8 36.0 18.4 113CC  
#119 Pos 21.2 15.0 29.0 28.0 36.6 28.0 24.5 37.0 30.0 34.0 12.0 119FB  
#130 Pos 21.0 16.0 20.0 29.0 37.4 22.0 23.0 28.0 25.0 38.0 7.0 130FA  
#856 Pos 20.0 12.0 22.0 23.0 37.5 24.0 24.0 35.0 25.0 36.0 0.0 130FC  
#868 Pos 25.0 17.9 29.0 33.5 41.5 39.0 26.0 38.5 26.0 43.5 9.0 151AC  
#543 Pos 15.0 12.0 23.0 27.0 38.0 25.0 20.0 31.0 25.0 41.0 9.0 206BC  
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#339 
 
 
Pos 25.0 10.0 23.0 30.0 37.0 28.5 21.7 33.0 26.0 38.3 0.0 327AB 
 
 
E 
#327 Pos 21.0 16.0 28.0 34.0 39.0 28.0 27.6 39.7 41.0 41.0 0.0 327AB E 
#980 Pos 20.0 15.0 24.0 21.0 36.0 23.0 12.0 33.0 20.0 37.0 0.0 418CC E 
#498 Pos 17.4 13.4 20.0 25.0 31.0 23.0 19.0 33.0 21.5 30.0 6.0 498AB  
#585 Pos 20.0 12.0 22.8 25.0 39.0 33.0 25.0 34.0 10.0 42.0 12.0 585CC  
#661 Pos 30.0 19.0 22.0 32.0 38.0 30.0 30.0 43.0 22.0 40.0 7.5 588DC  
#712 Pos 23.0 14.0 26.4 32.5 38.5 33.0 21.0 40.4 26.0 36.0 13.2 709CC F 
#709 Pos 18.5 15.0 22.0 28.8 38.0 26.8 25.0 36.0 23.6 33.0 12.0 709CC F 
#735 Pos 28.0 22.0 28.4 30.0 42.0 28.0 28.0 40.0 34.0 42.8 7.2 735DC  
#809 Pos 18.0 14.3 18.0 26.0 34.0 20.2 18.0 35.5 22.2 35.0 0.0 809EB  
#566 Pos 20.4 5.0 34.5 44.0 46.0 40.0 29.0 47.0 7.0 46.5 10.5 396AB D 
#359 Pos 22.0 20.0 22.0 57.0 52.0 60.0 18.0 38.0 48.6 62.0 16.0 359KG  
#691 Pos 14.0 12.4 30.0 34.0 18.0 33.0 25.0 38.0 24.0 42.0 10.0 206BC  
#813 Pos 40.3 38.0 37.4 49.0 38.1 52.0 39.0 24.0 32.0 50.6 45.0 151DC C 
#417 Pos 21.0 17.0 36.0 36.0 40.0 40.0 28.0 42.0 40.0 42.0 16.0 151DC C 
#830 Pos 18.7 15.7 28.0 40.0 42.6 34.0 25.0 19.0 27.0 39.0 17.0 109CC B 
#785 Pos 16.0 15.7 28.4 34.0 42.0 22.0 22.6 18.0 12.0 43.4 16.0 396AB D 
#250 Pos 10.0 12.0 23.0 26.0 24.0 22.2 11.0 30.0 16.0 26.0 0.0 077CC  
#056 Pos 20.0 9.0 26.0 24.0 38.3 22.0 18.0 30.0 32.6 10.0 0.0 056AB  
 Mean 20.3 14.8 25.3 31.1 37.5 29.3 22.8 34.3 25.0 37.8 8.3   
 Sd 5.7 5.5 4.8 8.1 5.9 9.3 5.6 6.4 8.8 8.5 9.2   
 +2 Sd 31.6 25.8 34.9 47.2 49.4 47.9 34.0 47.2 42.7 54.7 26.7   
 -2 Sd 8.9 3.9 15.7 15.0 25.6 10.7 11.6 21.4 7.3 20.9 -10.1   
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Table 2. t-test Results Comparing Susceptibility Between β-lactamase Producers and Non-
Producers in Response to 11 Antibiotics. 
 
I. Non-Cephalosporins       
       
Antibiotic Name β-lactamase        Mean             N            df          t         P 
Amoxicillin/Clavulanic Acid Producer 34.28 30 1 2.79 0.014 
  Non-Producer 41.59 11       
       
Aztreonam Producer 25.00 30 1 1.12 0.28 
  Non-Producer 29.50 11       
       
Imipenim Producer 22.81 30 1 3.91 0.002 
  Non-Producer 34.32 11       
       
Penicillin G Producer 10.14 30 1 12.05 <0.001 
  Non-Producer 38.20 11       
       
       
II. Cephalosporins       
       
Antibiotic Name  β-lactamase       Mean             N            df          t          P 
Cefaclor Producer 20.27 30 1 8.13 <0.001 
  Non-Producer 38.13 11       
       
Cefamandole Producer 14.85 30 1 8.05 <0.001 
  Non-Producer 38.05 11       
       
Cefixime Producer 25.26 30 1 2.7 0.018 
  Non-Producer 31.91 11       
       
Cefotaxime Producer 31.21 30 1 2.09 0.050 
  Non-Producer 41.59 11       
      
 
 
 
Ceftazidime Producer 37.51 30 1 1.36 0.190 
  Non-Producer 40.62 11       
       
Ceftriaxone Producer 29.31 30 1 3.29 0.005 
  Non-Producer 41.60 11       
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Table 2. Continued 
 
Cefuroxime Producer 22.81 30 1 3.91 0.002 
  Non-Producer 34.32 11       
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Table 3. Isolates Showing Deviant Susceptibility Patterns Based on Grubbs’ Outlier Test. 
Isolates are Sorted Based on β-lactamase Activity.  
 
β-lactamase –  Genotype ID #  Deviant Pattern    
   
 
Single Deviants 474KG 474  Imipenem susceptibility   
    
   123GE  123  Ceftazidime resistance   
    
 
Double Deviants 347AB  347  Cefaclor & Cefamandole susceptibility 
    
 
 
 
β-lactamase +  Genotype ID #  Deviant Pattern    
   
Single Deviants 206BC  691  Ceftazidime resistance    
   
   056AB  056  Imipenem resistance    
   
 
Double Deviants 359KG 359  Cefotaxime & Ceftriaxone susceptibility 
   
 
Triple Deviants 151DC  813  Cefixime, Cefamandole, Cefaclor &  
       Penicillin G susceptibility 
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CHAPTER 4  
DISCUSSION 
Purpose of Antibiotic Profiles 
 
 Antibiotic profiles were used to assess the susceptibility of M. catarrhalis isolates to a 
series of β-lactam antibiotics. β-lactamase is the primary antibiotic resistance factor for β-lactam 
antibiotics. Isolates that tested positive for β-lactamase production all displayed some degree of 
resistance, but there was evidence of variation in the resistance profiles among those β-lactamase 
positive isolates. Variation among β-lactamase producing isolates indicates that there must be a 
difference in the activity of the β-lactamase or other factors must influence resistance. For 
example, recent reports suggest that additional variation in BRO β-lactamase and/or in non-β-
lactamase factors may underlie novel susceptibility patterns (Baquero1996; Berk and Kalbfleisch 
1996). Other factors that may underlie antibiotic resistance include alterations in the target 
molecules that prevent interaction with the drug and/ or impermeability of the cell.  
Livermore et al. (2001) has offered a protocol for using antibiotic susceptibilities to guide 
strategies to manage resistance. Livermore suggested that first susceptibility testing be performed 
in order to determine those isolates that are resistant. Resistant isolates should then be subjected 
to an extensive battery of antibiotic tests (Livermore et al. 2001). The use of indicator drugs to 
detect the presence of a mechanism that gives resistance not only to the indicator itself, but also 
to related agents is another suggestion for detecting those isolates that are antibiotic resistant 
mutants (Livermore et al. 2001). Livermore further suggested that the information gathered from 
antibiotic profiles should be used to determine resistance patterns, especially indicating that β-
lactams are ideal drugs for discovering deviants.  
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This study used β-lactam antibiotics in a profile analysis of isolates from the VAMC. I 
suggest that deviant isolates may also be tested as suggested by Livermore in an effort to 
determine their resistance mechanism. Livermore suggested that ceftazidime can be used as an 
antibiotic indicator for most of the TEM and SHV-derived extended-spectrum β-lactamases 
(ESBL) types, while cefotaxime resistance is a better indicator for the CTX-M type enzymes in 
other countries (Livermore et al. 2001). From the VAMC, isolates and #691 of the β-lactamase 
producers showed increased resistance to ceftazidime hinting to the possibility of some variant 
alteration of the BRO β-lactamase, while isolate #123 of the β-lactamase non-producers showed 
decreased susceptibility to ceftazidime.  
Possible Modes of Antibiotic Resistance 
 
 The most frequent explanation for intrinsic antimicrobial resistance is explained by 
decreased accumulation of the antibiotic or impermeability (Thornsberry 1991). Impermeability 
to some β-lactam antibiotics may also be mediated by bacterial modifying enzymes that do not 
inactivate the compounds but rather bind to them and alter their structures (Thornsberry 1991).  
Alterations in antibacterial target molecules that prevent interaction with the antibiotic represents 
1 of the most important mechanisms to clinically used antibiotics (Thornsberry 1991). The 
cellular targets of β-lactam antibiotics are the penicillin binding proteins, and alterations in the 
binding sites are known to affect resistance to β-lactam antibiotics. Each of these mechanisms 
work together to confer a certain degree of antibiotic resistance and sometimes they work in 
conjunction with the β-lactamase enzyme.  
 Isolates that have the β-lactamase enzyme show resistance, but variation was present 
among the different β-lactamase positive isolates. In analyzing the susceptibility profiles to 
30 
penicillin, the only isolate that had a deviant profile was isolate #813. Isolate #813 also had a 
deviant profile for cefaclor, cefamandole, cefixime cefotaxime, ceftriaxone, and cefuroxime with 
statistically significant decreased resistance to those antibiotics. The profile of #813 suggests an 
additional factor that confers resistance among the β-lactamase positive isolates tested. Isolates # 
813 and #359 should be subjected to sequencing of the β-lactamase gene in order to determine if 
alterations exist in their ß-lactamases.  
Profiles in Genetically Identical Isolates 
 
 Comparisons of genetically identical isolates offer information on potential differences in 
β-lactamase activity. Isolates denoted by AA, BB, CC etc. in table 1 refer to groups of 
genetically identical isolates. There are evident differences in the susceptibility profiles of some 
genetically identical isolates. For example, among the β-lactamase positive isolates, there were 7 
different antibiotic profiles. Within those profiles the most profound discovery involved 3 
isolates that were genetically similar but differed in their β-lactamase activity. Genotype 109CC, 
(Table 1) included isolates #604 and #907 that were β-lactamase negative and isolate #830 that 
was β-lactamase positive. This genotype encompassed the entire spectrum of antibiotic 
resistance by phenotypes. Within genotype 109CC, isolate #604, a β-lactamase non-producer, 
showed relatively low susceptibility to cefuroxime but the remainder of its profile appeared 
similar to the genetically identical isolate #907. Isolate #907 had a profile that was typical of β-
lactamase non-producers. Isolate #830 had a profile similar to other β-lactamase producers with 
the exception of decreased susceptibility to amoxicillin/clavulanic acid. The antibiotic specific 
increase in resistance suggests a mutated β-lactamase gene may be present in isolate #830.  
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 Genotype 418CC, represented by isolates #944, #770, and #980 and genotype 709CC, 
represented by isolates #709 and #712, were each β-lactamase producers with typical profiles 
and no deviant isolates. In contrast, genotype 151DC was represented by isolates #813 and #417, 
which were also β-lactamase producers, but they represent a different end of the spectrum. 
Isolate #813 as previously mentioned, has an increased susceptibility to 7 out of the 11 
antibiotics tested, while isolate #417 displays increased susceptibility only to cefixime. The 
differences in profiles between isolates #813 and #417 continues to suggest that alterations in 
target site and/or decreased permeability may also work with the β-lactamase enzyme to aid in 
conferring antibiotic resistance. 
Alternative Hypotheses and Expectations 
 
Alternative hypotheses for the role of β-lactamase susceptibility include the scenario of 
β-lactamase as the sole determinant of β-lactamase resistance, in which case the susceptibilities 
of β-lactamase positive and β-lactamase negative isolates are not expected to overlap (Figure 
4a). The alternative hypothesis that β-lactamase has no influence on resistance predicts complete 
overlap of the susceptibilities (Figure 4b). A 3rd hypothesis is that if β-lactamase has some 
influence on the susceptibility, but it is not the sole determinant, then you would expect to see 
partial overlap. The susceptibility tests showed overlap in susceptibility, especially when 
comparing the cephalosporin antibiotics such as cefamandole with penicillin G (Fig. 5). The non-
cephalosporin, amoxicillin/clavulanic acid, used clinically as Augmentin also showed overlap of 
its susceptibility profiles indicating a β-lactamase affect with additional determinants that aid in 
explaining resistance to that antibiotic (Fig. 6). Also, in 9 of the 11 the antibiotic profiles 
compiled from the VAMC isolates, there existed overlap between the ß-lactamase producers and 
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non-producers, suggesting that β-lactamase is not the only determinant of resistance in the 
isolates tested. If other determinants were not essential to the resistance profiles we should 
expect that there would not be any difference between the isolates and how they react with the 
antibiotics.  
Suggestions for Future Projects 
 
 Those isolates determined to be different from the typical isolate (#831, #359, etc.) based 
on their antibiotic profile should be further analyzed. I suggest that the isolates determined to be 
ß-lactamase producers and that display unusual profiles should have their β-lactamase gene 
sequenced to determine the type of β-lactamase gene present. Based on the fact that 2 alleles are 
known that confer β-lactamase activity in M. catarrhalis, determining the type of allele present 
in those deviant isolates might offer important information about resistance.  
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Figure 4:  Diagrammatic Depiction of Expected Patterns in Susceptibility under Alternative  
    Hypothesis for Role of β-lactamase in Resistance 
 
 
 
a. Hypothesis 1: β-lactamase as Sole Determinant 
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b. Hypothesis 2: b-lactamase has No Effect 
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Figure 5. Cefamandole Antibiotic Susceptibility Profile.  Profile indicates a major β-lactamase effect 
                between the producers and non-producers. 
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Figure 6. Amoxicillin/clavulanic Acid Antibiotic Response.   Shows overlap in inhibition zones of 
β-lactamase producers and β-lactamase non-producers  
ANOVA P = 0.014 
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